Cargando…
An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates
The SARS-CoV-2 pandemic has affected more than 185 million people worldwide resulting in over 4 million deaths. To contain the pandemic, there is a continued need for safe vaccines that provide durable protection at low and scalable doses and can be deployed easily. Here, AAVCOVID-1, an adeno-associ...
Ejemplares similares
-
Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques
por: Zabaleta, Nerea, et al.
Publicado: (2022) -
Immunogenicity of an AAV-Based COVID-19 Vaccine in Murine Models of Obesity and Aging
por: Maciorowski, Dawid, et al.
Publicado: (2022) -
Computed tomography and [(18)F]-FDG PET imaging provide additional readouts for COVID-19 pathogenesis and therapies evaluation in non-human primates
por: Naninck, Thibaut, et al.
Publicado: (2022) -
Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection
por: Alexandre, Marie, et al.
Publicado: (2022) -
Impact of a PMMA tube on performances of a Vereos PET/CT system adapted for BSL-3 environment according to the NEMA NU2-2012 standard
por: Kahlaoui, Nidhal, et al.
Publicado: (2022)